Biotech Launch Readiness Assessment
Identify commercial gaps before they become launch problems.
Why Launch Readiness Matters
A launch plan may look comprehensive on paper while still containing significant commercial risk.
A launch-readiness assessment gives biotechnology leadership an independent view of whether the organization, strategy, capabilities and execution plans are genuinely prepared for commercialization.
PharmaKonsult evaluates readiness from the perspective of experienced commercial leadership.
What Is a Launch Readiness Assessment?
The assessment examines whether critical commercial decisions have been made, whether capabilities are developing at the right pace and whether functional plans align around the same commercial strategy.
The assessment should answer three questions:
- What is ready?
- What remains incomplete?
- What could materially affect launch performance if leadership does not address it?
Areas of Assessment
Market Understanding
Diagnosed patient population, addressable market, treatment pathway, referral network, customer concentration, physician behavior, competitor landscape and institutional dynamics.
Product Strategy
Target product positioning, differentiation, evidence gaps, potential adoption barriers, physician confidence and clinical-to-commercial narrative.
Market Access
Payer considerations, reimbursement, patient affordability, distribution, specialty pharmacy, patient support, prior authorization and access-related evidence.
Organization
Leadership, organizational design, hiring sequence, capability gaps, accountability and decision rights.
Cross-Functional Integration
Alignment between Commercial, Medical Affairs, Market Access, Clinical, Regulatory, Finance, Legal/Compliance, Supply Chain, Patient Services and Executive Leadership.
Execution
Roadmap, milestones, dependencies, risk tracking, measurement, governance and escalation processes.
Deliverable
A PharmaKonsult launch-readiness engagement should provide leadership with an executive assessment, identified strengths, commercial gaps, critical risks, priority actions, recommended sequencing, leadership considerations and a next-step roadmap.
When to Conduct an Assessment
- before major commercial hiring
- during Phase III
- before NDA/BLA submission
- 12–24 months before expected approval
- following major changes to the competitive landscape
- following leadership changes
- when a board requests additional commercial confidence
- when launch preparation appears behind schedule
The greatest value is often discovering what the organization does not know—while there is still time to act.
Related: First Commercial Launch, Biotech Commercialization Consulting.
How ready is your organization?
Request a confidential discussion with PharmaKonsult.
